PM₂.₅ (particulate matter with an aerodynamic diameter equal to or less than 2.5 micrometres) especially poses a serious risk to human health. It consists of particles with an aerodynamic diameter equal to or less than 2.5 micrometres. These particles can penetrate deep into the lung alveoli, while ultrafine particles can even enter the bloodstream and be transported throughout the entire body. The health effects associated with PM₂.₅ exposure are well documented and include both short-term and long-term impacts. In the short term, elevated concentrations of PM₂.₅ can lead to increased blood pressure, cardiac arrhythmias, and a higher incidence of emergency room and hospital admissions. Long-term exposure causes inflammation and oxidative stress, and increases the risk of respiratory diseases such as asthma, bronchitis, and lung cancer; cardiovascular diseases such as atherosclerosis and high blood pressure; metabolic disorders such as type 2 diabetes; and
neurological conditions including dementia.
The body of evidence is based on animal studies, experimental studies in humans, and large-scale epidemiological investigations. International institutions, including the United States Environmental Protection Agency (US EPA), have established a causal relationship between PM₂.₅ exposure and increased all-cause mortality and cardiovascular disease. In 2021, the WHO concluded that when PM₂.₅ levels rise by 10 micrograms per cubic metre of air, the risk of overall mortality increases by 8%. The risks of death from cardiovascular disease, respiratory conditions, and lung cancer grow considerably as well.
Older adults, children, and individuals with pre-existing respiratory or cardiovascular conditions are particularly affected. To date, no safe threshold has been identified below which adverse health effects are not expected to occur. Consequently, any reduction in PM₂.₅ exposure is considered beneficial to human health.